UK regulatory framework / C-031
UK regulation of experimental peptide products
Status follows the product, claims and route. A molecule name or disclaimer cannot determine whether a specific item is an authorised medicine.
Under the Human Medicines Regulations 2012, a product can be a medicine because it is presented as treating or preventing disease, or because it is used to modify physiological functions through pharmacological, immunological or metabolic action. The MHRA assesses status case by case. A “research use only” label does not replace that test.
This page explains the UK framework and official checks. It does not determine the legal status of a particular product or provide legal advice.
The two parts of the medicinal-product definition
Presentation
A substance or combination presented as having properties for treating or preventing disease in humans may meet the definition. Product pages, names, testimonials and social-media claims can contribute to presentation.
Function
A substance used or administered to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action may meet the definition. Either limb can be sufficient.
Source: Human Medicines Regulations 2012, regulation 2, and MHRA Guidance Note 8.
Authorised, unlicensed, investigational and unclear
For the full definitions, read licensed, unlicensed and investigational defined.
| Status | What it means | What it does not mean |
|---|---|---|
| Authorised medicine | A marketing authorisation covers a defined product, indication, formulation, strength and conditions of use. | The authorisation does not transfer to a separate vial carrying the same molecule name. |
| Unlicensed medicine | A medicine without a marketing authorisation. Limited lawful supply routes can exist under specific exemptions and professional responsibility. | Unlicensed does not automatically mean counterfeit, and it does not make open consumer sale lawful. |
| Investigational medicinal product | A medicine studied within a regulated clinical trial framework. | Investigational status is not marketing authorisation or consumer approval. |
| Unclear or disputed | The product facts, claims or intended function need regulatory assessment. | A seller's disclaimer cannot settle the classification. |
Use the official routes
How we record UK status
Each evidence record names the jurisdiction, product presentation, active substance, authorisation or database evidence, source date and any unresolved classification question. We do not copy the status of a licensed medicine onto an unrelated research-labelled item.
UK regulation questions
Is every unlicensed medicine illegal?
No. UK law provides limited routes for certain unlicensed medicines, such as specials supplied for a patient's special clinical need. This does not make a research-labelled consumer product lawful or equivalent to an authorised medicine.
Does a research use only label decide legal status?
No. The MHRA assesses products case by case using the legal definition, the way a product is presented and its function. A disclaimer is one piece of evidence, not a legal exemption.
How can I check whether a peptide medicine is authorised?
Search the MHRA products database by product name, active substance or Product Licence number. Read the product record and licence details, and treat a nil result as a prompt for further checks rather than a complete legal opinion.
Which MHRA route should I use to report a concern?
Use the suspicious seller service for possible illegal online supply. Use Yellow Card for a suspected side effect, defective medicine or fake healthcare product. Urgent symptoms need medical care first.
Primary legal and regulatory sources
- Human Medicines Regulations 2012, regulation 2Accessed 7 August 2026
- MHRA Guidance Note 8Accessed 7 August 2026
- MHRA borderline products guidanceAccessed 7 August 2026
- MHRA products databaseAccessed 7 August 2026
- the UK guidance logSources checked 9 August 2026
Editorial experience
From our work: how we checked this page
For topical-map item C-031, UK regulation of experimental peptide products was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.